Source: Reuters.com

Mon Oct 19, 2009 8:31am EDT

Updated NCCN Guidelines for AML Include Risk Stratification to Assist in
Treatment Selection


The National Comprehensive Cancer Network (NCCN) recently updated the NCCN
Guidelines for Acute Myeloid Leukemia (AML), the most common acute leukemia
affecting adults. Noteworthy updates include the incorporation of risk
stratification based on white blood cell count, the alternative to...

admin

Tue Oct 6, 2009 11:49pm IST

* FDA fails to approve Clolar in elderly adults with AML

* Agency says Genzyme needs to conduct additional trial

* Result was expected; Genzyme's shares up 1.7 percent

BOSTON, Oct 6 (Reuters) - Genzyme Corp said on Tuesday that U.S. regulators will not allow the company to market its leukemia drug Clolar to previously untreated older adults unless it completes an additional clinical trial.

Clolar is currently...

admin

By John Gever, Senior Editor, MedPage Today
Published: August 28, 2009


An application to market clofarabine (Clolar) for treating acute myeloid leukemia (AML) in patients 60 and older has received a cool reception from FDA staff.

The agency's staff review, released in advance of an Oncologic Drugs Advisory Committee meeting next week, was critical of the data submitted by the drug's manufacturer, Genzyme.

It said the company failed to perform a...

admin

Last Updated: 2009-03-02 17:25:16 -0400 (Reuters Health)

NEW YORK (Reuters Health) - In elderly acute myeloid leukemia (AML) patients undergoing autologous stem cell transplantation (ASCT), a conditioning regimen consisting of 2 days of continuous infusion idarubicin at a dose of 20 mg/m²/d followed by 3 days oral or IV busulphan (4mg/kg/d) is safe and has the potential to prolong the duration of complete remission and survival, a study shows.

"Best results are achievable...

admin